PRA Health Sciences (NASDAQ:PRAH) was downgraded by stock analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a report released on Friday.
A number of other analysts have also issued reports on PRAH. SunTrust Banks raised their target price on shares of PRA Health Sciences to $120.00 and gave the stock a “buy” rating in a research report on Monday, November 5th. Robert W. Baird raised their target price on shares of PRA Health Sciences from $112.00 to $116.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 11th. Evercore ISI assumed coverage on shares of PRA Health Sciences in a research report on Thursday, October 4th. They set an “inline” rating and a $120.00 target price on the stock. Finally, UBS Group assumed coverage on shares of PRA Health Sciences in a research report on Tuesday, October 9th. They set a “neutral” rating on the stock. Two investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. PRA Health Sciences presently has a consensus rating of “Buy” and an average price target of $111.50.
Shares of NASDAQ PRAH opened at $106.34 on Friday. PRA Health Sciences has a 1 year low of $79.20 and a 1 year high of $121.98. The company has a market cap of $7.20 billion, a P/E ratio of 33.23, a PEG ratio of 1.60 and a beta of 0.77. The company has a current ratio of 0.89, a quick ratio of 0.89 and a debt-to-equity ratio of 1.22.
PRA Health Sciences (NASDAQ:PRAH) last announced its earnings results on Wednesday, October 31st. The medical research company reported $1.13 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.07 by $0.06. PRA Health Sciences had a net margin of 2.37% and a return on equity of 25.75%. The firm had revenue of $717.60 million for the quarter, compared to analyst estimates of $729.63 million. During the same quarter last year, the business earned $0.88 earnings per share. PRA Health Sciences’s revenue was up 23.3% compared to the same quarter last year. Sell-side analysts anticipate that PRA Health Sciences will post 3.93 earnings per share for the current year.
A number of large investors have recently bought and sold shares of PRAH. Janney Montgomery Scott LLC raised its stake in PRA Health Sciences by 18.1% during the second quarter. Janney Montgomery Scott LLC now owns 8,151 shares of the medical research company’s stock worth $761,000 after purchasing an additional 1,250 shares during the period. Aperio Group LLC raised its stake in PRA Health Sciences by 22.5% during the second quarter. Aperio Group LLC now owns 7,575 shares of the medical research company’s stock worth $707,000 after purchasing an additional 1,393 shares during the period. Crossmark Global Holdings Inc. purchased a new position in PRA Health Sciences during the second quarter worth approximately $747,000. New Mexico Educational Retirement Board purchased a new position in PRA Health Sciences during the second quarter worth approximately $1,111,000. Finally, Comerica Bank raised its stake in PRA Health Sciences by 1,390.2% during the second quarter. Comerica Bank now owns 38,493 shares of the medical research company’s stock worth $3,827,000 after purchasing an additional 35,910 shares during the period. 97.42% of the stock is currently owned by institutional investors.
PRA Health Sciences Company Profile
PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.
Recommended Story: Correction
Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.